Comparative Pharmacology
Head-to-head clinical analysis: CORTISONE ACETATE versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTISONE ACETATE versus EOHILIA.
CORTISONE ACETATE vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
25-300 mg per day orally, in divided doses every 6-12 hours, depending on condition severity.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
Clinical Note
moderateCortisone acetate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin."
Clinical Note
moderateCortisone acetate + Rosoxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin."
Clinical Note
moderateCortisone acetate + Levofloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin."
Clinical Note
moderate30 minutes (plasma half-life of cortisol); biological half-life 8-12 hours (due to intracellular receptor binding and transcriptional effects)
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Renal (approximately 90% as metabolites, <5% unchanged); biliary/fecal (<5%)
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category C
Category C
Corticosteroid
Corticosteroid
Cortisone acetate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trovafloxacin."